Accord Healthcare: Hetronifly® receives Marketing Authorisation from the European Commission , for the treatment of Extensive-Stage Small Cell Lung Cancer

Hetronifly is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC (in combination with carboplatin and etoposide).Hetronifly is the only anti-PD-1 mAb approved in Europe for the treatment of ES-SCLC and is already approved in China, and several Southeast Asian countries.In December 2022, Hetronifly received orphan drug designation from the EC for the treatment of SCLC, which was renewed in 2025.The European Society for Medical Oncology (ESMO) scores serplulimab 4 out of 5 on their magnitude of clinical benefit scale (MCBS) in ES-SCLC.View original content:https://www.prnewswire.co.uk/news-releases/accord-healthcare-hetronifly-serplulimab-receives-marketing-authorisation-from-the-european-commission-ec-for-the-treatment-of-extensive-stage-small-cell-lung-cancer-es--sclc-302369448.html